Article metrics

Original research
Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)

 

Online download statistics by month:

Online download statistics by month: March 2022 to April 2024

AbstractFullPdf
Mar 2022324330110
Apr 202213914760
May 202211011035
Jun 202212813155
Jul 202212112121
Aug 202211811856
Sep 202213113135
Oct 202210110435
Nov 2022888920
Dec 2022919121
Jan 202310210223
Feb 2023858528
Mar 2023565750
Apr 2023343437
May 2023494926
Jun 2023434322
Jul 2023434320
Aug 2023383820
Sep 2023252510
Oct 2023464615
Nov 202336366
Dec 2023505110
Jan 2024383817
Feb 2024343428
Mar 2024555562
Apr 2024535331
Total21382161853